Here are the 424B prospectus supplements from Veradermics, Incorporated (MANE) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow MANE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MANE filings page.
Veradermics, Incorporated has filed a prospectus covering the potential resale by existing investors of up to 16,772,058 shares of common stock and 300,000 shares issuable upon exercise of pre-funded warrants with a strike price of $0.00001 per share. These are secondary sales by selling stockholders; Veradermics is not selling any shares in this offering and will receive no proceeds from resales, other than any cash paid upon warrant exercise.
The resale shares represent about 40.6% of the company’s outstanding common stock as of August 6, 2026, creating potential stock overhang. Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on pattern hair loss, developing VDPHL01, an oral extended-release minoxidil formulation intended to improve hair growth while limiting cardiac side effects. The company is listed on the NYSE under the symbol MANE, with a last reported price of $111.00 on August 13, 2026, and qualifies as both an emerging growth company and a smaller reporting company.
Veradermics is offering 3,843,790 shares of common stock at $100.00 per share to raise gross proceeds of $384,379,000. The company concurrently agreed to sell pre-funded warrants in a private placement (PIPE) for 300,000 shares at $99.99999 each to affiliates of Suvretta Capital; those pre-funded warrants are immediately exercisable, subject to ownership limits. Net proceeds from the offering and PIPE are estimated at approximately $388.8 million (or $443.0 million if the underwriters’ option is fully exercised), which the company intends to use for commercial launch activities, manufacturing expansion, clinical development and general corporate purposes.